Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No RS - I agree. Ends up going down further if no substantial news.
Looking for double bottom at .70 now. Hopefully it holds.
They have been eliminating positions to match expenses vs sales. You don't need sales reps when you are selling less.
I do the opposite!
Bottom is in. Birdman sold some PRED today!!
Level 2 is here
https://www.otcmarkets.com/stock/ABML/quote
Chart has a double top now.
Heard the same.
Thanks HP. Good info
That's the plan
Convertible debt and no current funding. Just notes of optimism and pumping lately. Note they issued 10M shares to themselves today as compensation since they are strapped for cash.
They still don't have the money so be careful up here.
Lots of pumping today. Cut my position size into the strength today.
I love it but whatever happened to commercialization?
Yea he is. But he got the info from a more reliable source. But RAFA that is another story. It's not moving much probably because of him.
I agree. For Rafa it's not a 35 or 45 stock, it's maybe 3.50 to 4.50
Those shares were convertible to 100 common each. Read the filing.
They will likely do a reverse split soon just like they will do with BFNH
What is clear is that PRED is very slow to execute. I hope this changes soon.
Spoke with IR today. Details surrounding the selling of the various diagnostic kits will be included in the Q2 ER press release next week. That's all I know.
Link doesn't seem to be working
They seem very slow to execute on these testing kits.
Don't believe a word he says. He has no inside connections to the company.
Settled with no liability to any party. Another words, only the lawyers got anything.
Note they are FDA compliant but they are not FDA approved for any indication. That's why they are conducting trials for RA in the knee. Once FDA approved they could be covered by insurance and advertised for such indication.
Thus the treatments are only as good as the doctors administrating them are. That's where the issues are. Lots of quacks out there don't know what they are doing. Of course, some do and are successful in the treatments.
Disregard Ameritrade incorrect it would seem
Well over 2MM shares traded last 3 minutes today according to TD AmeriTrade
They usually don't do PRs on Mondays or Fridays anyway, right?
Article about BASF mentioning ABML
https://www.greentownlabs.com/basf-advises-circularity-challenge-startups-on-navigating-corporate-venture-capital-arm/
TL did they say when EndoRisk will be introduced?
ABML is one of two partners listed of VCM Group (AU)
https://vcmgroup.com.au/
Snake - totally agree. He's a typical "investor that buys high and sells low" like he did with PRED. Claims he lost $170K on PRED. Well dumb ass, that's what happens when you sell low (below a buck) when smart investors are buying.
The trades he does win on are typically gains below 25 cents a share.
Overall just do the opposite and you'll make money.
No formal presentation was made
I don't believe the company gave the presentation in any formal session; most likely in 1:1 small meetings with key people.
Barry - there's the problem!
Don't forget this only one out of 20+ diseases that they will have diagnostic tools for!!!
Very true. Thanks for pointing that out! True for all those numbers.
Based upon the numbers, EndoRisk appears to be based upon entire addressable population now. The others are based upon number of women visiting the clinic for an issue.
But yes, at least they are showing us something for a change.
This test (Endorisk)will most likely be given my regular Gyns; not just reproductive specialists.
It could indicate the potential pent up demand initially (cumulatively for the next 5-10 years (just a guess)) but be 5% of those numbers on an annual basis several years out.